- Home
- XPEL vs ELVN Comparison
XPEL vs ELVN Comparison
Compare XPEL & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPEL
- ELVN
- Stock Information
- Founded
- XPEL 1999
- ELVN 2016
- Country
- XPEL United States
- ELVN United States
- Employees
- XPEL N/A
- ELVN N/A
- Industry
- XPEL Industrial Specialties
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- XPEL Industrials
- ELVN Health Care
- Exchange
- XPEL Nasdaq
- ELVN Nasdaq
- Market Cap
- XPEL 999.3M
- ELVN 1.2B
- IPO Year
- XPEL N/A
- ELVN 2020
- Fundamental
- Price
- XPEL $39.34
- ELVN $20.73
- Analyst Decision
- XPEL Strong Buy
- ELVN Strong Buy
- Analyst Count
- XPEL 1
- ELVN 5
- Target Price
- XPEL $58.00
- ELVN $41.20
- AVG Volume (30 Days)
- XPEL 173.8K
- ELVN 747.2K
- Earning Date
- XPEL 08-07-2025
- ELVN 08-12-2025
- Dividend Yield
- XPEL N/A
- ELVN N/A
- EPS Growth
- XPEL N/A
- ELVN N/A
- EPS
- XPEL 1.71
- ELVN N/A
- Revenue
- XPEL $434,101,000.00
- ELVN N/A
- Revenue This Year
- XPEL $11.20
- ELVN N/A
- Revenue Next Year
- XPEL $11.18
- ELVN N/A
- P/E Ratio
- XPEL $22.94
- ELVN N/A
- Revenue Growth
- XPEL 8.38
- ELVN N/A
- 52 Week Low
- XPEL $24.25
- ELVN $13.30
- 52 Week High
- XPEL $48.58
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- XPEL 65.72
- ELVN 52.08
- Support Level
- XPEL $35.40
- ELVN $19.22
- Resistance Level
- XPEL $36.61
- ELVN $21.90
- Average True Range (ATR)
- XPEL 1.19
- ELVN 1.49
- MACD
- XPEL 0.15
- ELVN -0.19
- Stochastic Oscillator
- XPEL 97.34
- ELVN 39.43
About XPEL XPEL Inc.
XPEL Inc is a supplier of protective films, coatings, and related services to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from the sale of automotive products and related services while the remainder of its revenue is derived from non-automotive products including architectural window film and marine and flat surface protection films. The majority of revenue is derived from the United States.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.